Lyka Labs Limited (LYKALABS.NS)
INR 156.41
(1.68%)
INR 156.41
(1.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 167.58 Million INR | -21.18% |
| 2022 | 128.46 Million INR | -80.55% |
| 2021 | 1.01 Billion INR | 389.54% |
| 2020 | 196.83 Million INR | 459.88% |
| 2019 | -26.16 Million INR | -254.3% |
| 2018 | -16.42 Million INR | 58.74% |
| 2017 | -25.16 Million INR | -124.19% |
| 2016 | 208.7 Million INR | -6.83% |
| 2015 | 284.16 Million INR | 5.3% |
| 2014 | 275.8 Million INR | 784.7% |
| 2013 | -24.49 Million INR | -119.88% |
| 2012 | 312.17 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 252.29 Million INR | 33.72% |
| 2009 | 193.12 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 37.07 Million INR | 82.08% |
| 2023 Q2 | 44.24 Million INR | 46.51% |
| 2023 FY | - INR | -21.18% |
| 2023 Q3 | 74.06 Million INR | 67.4% |
| 2023 Q1 | 30.19 Million INR | -11.7% |
| 2023 Q4 | 20.28 Million INR | -72.62% |
| 2022 Q3 | 32.78 Million INR | -47.27% |
| 2022 Q2 | 62.18 Million INR | -11.42% |
| 2022 Q1 | 70.19 Million INR | -43.42% |
| 2022 FY | - INR | -80.55% |
| 2022 Q4 | 34.2 Million INR | 4.32% |
| 2021 Q3 | 134.24 Million INR | -71.01% |
| 2021 Q2 | 463.15 Million INR | 52.51% |
| 2021 Q1 | 303.68 Million INR | 367.77% |
| 2021 FY | - INR | 389.54% |
| 2021 Q4 | 124.07 Million INR | -7.58% |
| 2020 Q2 | 38.23 Million INR | -11.63% |
| 2020 FY | - INR | 459.88% |
| 2020 Q3 | 62.99 Million INR | 64.75% |
| 2020 Q4 | 64.92 Million INR | 3.06% |
| 2020 Q1 | 43.26 Million INR | 214.7% |
| 2019 Q4 | -37.72 Million INR | -265.87% |
| 2019 Q1 | -7.23 Million INR | 65.69% |
| 2019 FY | - INR | -254.3% |
| 2019 Q2 | -2.92 Million INR | 59.5% |
| 2019 Q3 | -10.31 Million INR | -252.0% |
| 2018 Q2 | -44.04 Million INR | -2358.51% |
| 2018 Q4 | -21.07 Million INR | -148.32% |
| 2018 FY | - INR | 58.74% |
| 2018 Q1 | 1.95 Million INR | 0.0% |
| 2018 Q3 | 43.61 Million INR | 199.04% |
| 2017 FY | - INR | -124.19% |
| 2016 Q1 | 26.29 Million INR | -71.75% |
| 2016 FY | - INR | -6.83% |
| 2016 Q4 | 69.44 Million INR | 6.06% |
| 2016 Q3 | 65.47 Million INR | -17.25% |
| 2016 Q2 | 79.12 Million INR | 200.96% |
| 2015 Q2 | 69.12 Million INR | -34.97% |
| 2015 Q4 | 93.06 Million INR | 160.19% |
| 2015 Q3 | 35.76 Million INR | -48.25% |
| 2015 Q1 | 106.3 Million INR | 104.78% |
| 2015 FY | - INR | 5.3% |
| 2014 Q2 | 54.56 Million INR | 345.76% |
| 2014 Q1 | 12.24 Million INR | 0.0% |
| 2014 Q4 | 51.9 Million INR | -68.47% |
| 2014 Q3 | 164.63 Million INR | 201.7% |
| 2014 FY | - INR | 784.7% |
| 2013 Q3 | 27.18 Million INR | -43.47% |
| 2013 FY | - INR | -119.88% |
| 2013 Q1 | 46.85 Million INR | 64.27% |
| 2013 Q2 | 48.08 Million INR | 2.63% |
| 2012 Q2 | 76.2 Million INR | 9.77% |
| 2012 Q4 | 28.52 Million INR | 154.68% |
| 2012 Q3 | -52.16 Million INR | -168.45% |
| 2012 FY | - INR | 0.0% |
| 2012 Q1 | 69.42 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | -13.17 Million INR | 0.0% |
| 2010 FY | - INR | 33.72% |
| 2009 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 99.596% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | 92.689% |
| Concord Biotech Limited | 4.65 Billion INR | 96.403% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | 94.544% |
| Jubilant Ingrevia Limited | 4.56 Billion INR | 96.328% |
| Panacea Biotec Limited | -47.58 Million INR | 452.226% |
| Piramal Pharma Limited | 13.05 Billion INR | 98.716% |
| SMS Lifesciences India Limited | 349.41 Million INR | 52.037% |
| Supriya Lifescience Limited | 1.83 Billion INR | 90.871% |
| Syngene International Limited | 10.84 Billion INR | 98.455% |
| TAKE Solutions Limited | -1.05 Billion INR | 115.948% |
| Zota Health Care Limited | 82.07 Million INR | -104.195% |